{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In patients enrolled in the COSS trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with and without recurrent hemispheric syndromes associated with AICAO"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomization into surgical vs medical groups"
      },
      "Objective": {
        "score": 1,
        "evidence": "To compare clinical outcomes and efficacy of EC-IC bypass surgery"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was all stroke and death from randomization through 30 d and ipsilateral ischemic stroke within 2 yr."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of 195 randomized participants, 100 were rHEMI+ (50 in each group)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Baseline characteristics between rHEMI+ and rHEMI\u2212 participants were similar"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "no significant differences in occurrence of the primary endpoint between nonsurgical and surgical participants in rHEMI+ (26.3% vs 22.4%, P = .660)"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  },
  "model": "gpt-4o"
}